Q4 2024 Earnings Call Transcript March 18, 2025 MiNK Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Equities research analysts at William Blair issued their Q1 2025 earnings per share estimates for MiNK Therapeutics in a ...

MiNK Therapeutics Inc (INKT) showcases promising clinical progress and strategic partnerships while navigating financial hurdles and leadership changes.

We ended the year with a cash balance of $4.6 million. Cash used in operations for the three and twelve months ended December 31, 2024, was $1.7 million, and $9.6 million, respectively, compared to $3 ...

Hello, everyone, and welcome to MiNK Therapeutics fourth-quarter 2024 financial results call. Please note that this call is being recorded. (Operator Instructions) I'd now like to hand the call over ...

MiNK advanced its mission to bring off-the-shelf iNKT cell therapies to patients fighting hard-to-treat cancers and severe ...

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in invariant natural killer T (iNKT) cell therapies, announced its financial results for the fourth quarter and ...